
DexCom (DXCM) Stock Forecast & Price Target
DexCom (DXCM) Analyst Ratings
Bulls say
DexCom has achieved record new patient starts in Q3 2024, reflecting strong demand for its continuous glucose monitoring systems and solid core growth in international markets. The company is projected to see an increase in EBITDA margin from 28% in 2023 to approximately 29% in 2024, with expectations of reaching 31% by 2025, indicating a positive trend in profitability. Additionally, the ongoing expansion of its prescriber base and stabilization in the durable medical equipment channel are expected to contribute to robust sales growth, with projected year-over-year growth of at least 15% in 2025.
Bears say
The negative outlook on DexCom's stock is primarily driven by a 2% year-over-year decline in revenue in the U.S. for the second quarter of 2024, despite a more than 20% increase in the installed base. Additionally, the company has lost incremental market share in the durable medical equipment (DME) channel and is facing pricing pressures as its pricing begins to align more closely with competitors following the integration of automatic insulin delivery systems. Furthermore, management's guidance suggests that future growth in the Type 1 diabetes segment is likely to be more subdued than previously anticipated.
This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.
DexCom (DXCM) Analyst Forecast & Price Prediction
Start investing in DexCom (DXCM)
Order type
Buy in
Order amount
Est. shares
0 shares